

SYNLAB Agreements Signed in Türkiye and Czech Republic

- Microba and SYNLAB continue to expand distribution of Microba's testing technology across Europe
- Microba has executed two further distribution agreements with SYNLAB affiliate organisations in Türkiye (formerly known as Turkey) and Czech Republic
- This further adds to the new agreements executed with SYNLAB affiliate organisations in December for Italy and Portugal

Microba Life Sciences Limited (ASX: MAP) ("Microba") is pleased to announce that agreements have been executed with SYNLAB International GmbH ("SYNLAB") (ETR: SYAB) affiliate organisations Referans M-B Saglik Labopraturar and SYNLAB czech s.r.o., to distribute Microba's testing technology into Türkiye and Czech Republic respectively.

Microba's Senior Vice President - Services, Mr Bernie Woodcroft said, *"We continue to progress distribution expansion with SYNLAB, Europe's largest medical diagnostics company, to drive our testing into the hands of clinicians and patients across Europe. Adding Türkiye and Czech Republic is another positive step forward in the global distribution expansion of Microba's testing services"*.

In 2020, Microba entered into a master agreement with SYNLAB International GmbH and an agreement with SYNLAB Diagnosticos Globales to deliver Microba's testing to Healthcare Providers in Spain, with an option to formalise distribution agreements across their affiliate organisations, which operate in 36 countries. With positive sales and customer feedback in Spain, in October 2022 SYNLAB further activated their rights through an amendment to the master agreement with Microba to pursue formal expansion into additional countries across Europe and Latin America. Aligned to this, in December a first group of new agreements were signed with SYNLAB affiliate organisations for Italy and Portugal respectively, which have now been operationalised and achieved first sales.

Additional agreements have now been signed with SYNLAB affiliate organisations for Türkiye and Czech Republic respectively, which provide them with non-exclusive distribution rights out to 31 December 2028.

Entry into both Türkiye and Czech Republic, represents another positive advancement in distribution with Europe's largest medical diagnostics company. Further affiliate country agreements are anticipated to be completed in the near term to continue this expansion activity with SYNLAB.

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

E: Luke.Reid@microba.com

Simon Hinsley

Investor / Media Relations

E: simon@nwrcommunications.com.au

T: +61 401 809 653

About SYNLAB

SYNLAB Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporates. SYNLAB operates in 36 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. Around 30,000 employees, including over 2,000 medical experts, contribute every day to the Group's worldwide success.

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.